<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107414">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01689363</url>
  </required_header>
  <id_info>
    <org_study_id>API-H001-CLN-A2</org_study_id>
    <nct_id>NCT01689363</nct_id>
  </id_info>
  <brief_title>Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)</brief_title>
  <acronym>H001-A2</acronym>
  <official_title>A Randomized, Double-Blinded, Negative- and Positive-Controlled Study for Evaluation of the Allergenicity of Amphadase® in Healthy Volunteers Using Intradermal Skin Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amphastar Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amphastar Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the allergenicity of Amphadase® in healthy volunteers
      using an intradermal skin test.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>Development of allergic skin reaction</measure>
    <time_frame>30 minutes after dosing</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary endpoint for this study is the &quot;allergenicity of Amphadase&quot; by means of an intradermal skin testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of allergic skin reaction</measure>
    <time_frame>24 hours after dosing</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary endpoint for this study is the &quot;allergenicity of Amphadase&quot; by means of an intradermal skin testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The level of allergenicity of Amphadase®</measure>
    <time_frame>After Dosing: 30 minutes and 24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The skin responses, in terms of the greater diameters of the wheal and/or the erythema etc., will be analyzed for the three (3) study  treatments.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>within 24 hours after dosing</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events, such as systemic reaction or other anaphylaxis, will be closely monitored and documented when observed by investigators or reported by subjects during the study period.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">263</enrollment>
  <condition>Allergic Skin Reaction</condition>
  <arm_group>
    <arm_group_label>Hyaluronidase Intradermal Injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection with negative control (saline)and 1 injection with Positive control (histamine) Two injections with the test drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronidase Intradermal Injection</intervention_name>
    <description>Intradermal injection of the study drug (2 injections) One injection with a positive control and one with a negative control</description>
    <arm_group_label>Hyaluronidase Intradermal Injections</arm_group_label>
    <other_name>Amphadase®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy volunteers of either gender; Those without clinically significant cardiovascular
        gastrointestinal, hepatic, neurological, psychiatric, endocrine, or other major systemic
        disease that would unduly risk the subject's safety or interfere with the interpretation
        of results, assessed according to the judgment of the Principal Investigator. A
        non-inclusive list which would not be exclusionary and define healthy individual for the
        purposes of this study are:

          -  hypothyroidism,

          -  stable hypertension except those subjects on beta blockers including  ocular
             preparations,

          -  seasonal/perennial allergic rhinitis if able to wash out of antihistamines,

          -  stable, mild intermittent asthma (subjects using beta agonists as a monotherapy on an
             as-needed basis, excluding daily usage),

          -  migraine if not taking excluded medications,

          -  mild anxiety/depression if not taking excluded medications, and

          -  mild arthritic conditions if not taking excluded medications.

          -  Willingness and ability to sign an informed consent document;

          -  18 - 80 years of age;

          -  Intact skin at the forearm ;

          -  Female participants are currently practicing effective birth control methods or
             abstinence.

        Exclusion Criteria:

          -  Known allergy, hypersensitivity or contraindications to hyaluronidase, thimerosal,
             edetate disodium (EDTA);

          -  Use of medications within a duration considered to interfere with skin testing.

          -  Known dermographism which may interfere with skin testing.

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selina Su, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>A:mphastar Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Research Group</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baker Allergy, Asthma &amp; Dermatology Research Center, LLC</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainer Center for Clinical Research, Inc</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma Inc</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Barr J, Kirkpatrick N, Dick A, Leonard L, Hawksworth G, Noble DW. Effects of adrenaline and hyaluronidase on plasma concentrations of lignocaine and bupivacaine after peribulbar anaesthesia. Br J Anaesth. 1995 Dec;75(6):692-7.</citation>
    <PMID>8672315</PMID>
  </reference>
  <reference>
    <citation>Brydon CW, Basler M, Kerr WJ. An evaluation of two concentrations of hyaluronidase for supplementation of peribulbar anaesthesia. Anaesthesia. 1995 Nov;50(11):998-1000.</citation>
    <PMID>8678264</PMID>
  </reference>
  <reference>
    <citation>Ahluwalia HS, Lukaris A, Lane CM. Delayed allergic reaction to hyaluronidase: a rare sequel to cataract surgery. Eye (Lond). 2003 Mar;17(2):263-6. Review.</citation>
    <PMID>12640426</PMID>
  </reference>
  <reference>
    <citation>Agrawal A, McLure HA, Dabbs TR. Allergic reaction to hyaluronidase after a peribulbar injection. Anaesthesia. 2003 May;58(5):493-4.</citation>
    <PMID>12694021</PMID>
  </reference>
  <reference>
    <citation>Kempeneers A, Dralands L, Ceuppens J. Hyaluronidase induced orbital pseudotumor as complication of retrobulbar anesthesia. Bull Soc Belge Ophtalmol. 1992;243:159-66.</citation>
    <PMID>1302146</PMID>
  </reference>
  <reference>
    <citation>Minning CA Jr. Hyaluronidase allergy simulating expulsive choroidal hemorrhage. Arch Ophthalmol. 1994 May;112(5):585-6.</citation>
    <PMID>8185511</PMID>
  </reference>
  <reference>
    <citation>Szépfalusi Z, Nentwich I, Dobner M, Pillwein K, Urbanek R. IgE-mediated allergic reaction to hyaluronidase in paediatric oncological patients. Eur J Pediatr. 1997 Mar;156(3):199-203.</citation>
    <PMID>9083759</PMID>
  </reference>
  <reference>
    <citation>Allergy testing. American College of Physicians. Ann Intern Med. 1989 Feb 15;110(4):317-20.</citation>
    <PMID>2578014</PMID>
  </reference>
  <reference>
    <citation>Poulsen LK. In vivo and in vitro techniques to determine the biological activity of food allergens. J Chromatogr B Biomed Sci Appl. 2001 May 25;756(1-2):41-55. Review.</citation>
    <PMID>11419727</PMID>
  </reference>
  <reference>
    <citation>Howard A, Mercer P, Nataraj HC, Kang BC. Bevel-down superior to bevel-up in intradermal skin testing. Ann Allergy Asthma Immunol. 1997 Jun;78(6):594-6.</citation>
    <PMID>9207725</PMID>
  </reference>
  <reference>
    <citation>Barbaud A, Reichert-Penetrat S, Tréchot P, Jacquin-Petit MA, Ehlinger A, Noirez V, Faure GC, Schmutz JL, Béné MC. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998 Jul;139(1):49-58.</citation>
    <PMID>9764148</PMID>
  </reference>
  <reference>
    <citation>Fisher MM, Bowey CJ. Intradermal compared with prick testing in the diagnosis of anaesthetic allergy. Br J Anaesth. 1997 Jul;79(1):59-63.</citation>
    <PMID>9301390</PMID>
  </reference>
  <reference>
    <citation>Ruzicka T, Gerstmeier M, Przybilla B, Ring J. Allergy to local anesthetics: comparison of patch test with prick and intradermal test results. J Am Acad Dermatol. 1987 Jun;16(6):1202-8.</citation>
    <PMID>3597862</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 22, 2013</lastchanged_date>
  <firstreceived_date>September 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyaluronidase</keyword>
  <keyword>enzymes with tissue spreading activity</keyword>
  <keyword>allergic reaction</keyword>
  <keyword>intradermal skin testing</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
